CML06

Australasian Leukaemia and Lymphoma Group (ALLG)

Timothy Hughes (Institute of Medical and Veterinary Science)

Dataset includes:

• Data for 21 patients with newly diagnosed CML
• Combination of Pegasys and Glivec treatment.
• Dataset includes demographic data, diagnostic, treatment data, outcome data

Australasian Leukaemia and Lymphoma Group (ALLG)

Cancer therapy (excl. chemotherapy and radiation therapy)

• In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
• Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL
• Measurement of In Vivo BCR-ABL Kinase Inhibition to Monitor Imatinib-Induced Target Blockade and Predict Response in Chronic Myeloid Leukemia
• Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
• Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
• Classification of Patients With Chronic Myeloid Leukemia on Basis of BCR-ABL Transcript Level at 3 Months Fails to Identify Patients With Low Organic Cation Transporter-1 Activity Destined to Have Poor Imatinib Response
• Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
• BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
• Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au